Pre-existing antiacetylcholine receptor autoantibodies and B cell lymphopaenia are associated with the development of myositis in patients with thymoma treated with avelumab, an immune checkpoint inhibitor targeting programmed death-ligand 1

既往存在的抗乙酰胆碱受体自身抗体和B细胞淋巴细胞减少症与接受avelumab（一种靶向程序性死亡配体1的免疫检查点抑制剂）治疗的胸腺瘤患者发生肌炎相关。